Events
Dr. Figueroa received her MD from Universidad del Salvador, School of Medicine in Buenos Aires, Argentina in 1997. After completing her internal medicine residency, she went on to train as a hematologist at the Institute for Hematological Research “Mariano Castex” at the National Academy of Medicine in Buenos Aires, where she later joined the Malignant Hematology Department. In 2004 Dr. Figueroa joined Dr. Ari Melnick’s laboratory in New York. During her postdoctoral training with Dr. Melnick, Dr. Figueroa’s research focused on the characterization of epigenetic deregulation in myeloid malignancies, particularly Acute Myeloid Leukemia and Myelodysplastic Syndromes.
In 2011 Dr. Figueroa started her independent career as an Assistant Professor at the University of Michigan Medical School, where she continued her work in the field of epigenetic regulation of normal and malignant hematopoiesis. In September 2016 she was recruited as Associate Professor to the University of Miami Miller School of Medicine where she also served as the Co-Leader Cancer Epigenetics Research Program for the Sylvester Comprehensive Cancer Center until 2023. In June 2023, Dr Figueroa was promoted to the role of Associate Director for Translational Research for the Sylvester Comprehensive Cancer Center. Throughout her career, Dr. Figueroa has been the recipient of scholar awards from the SASS Foundation for Cancer Research, the American Society of Hematology, The Leukemia and Lymphoma Society, and the Doris Duke Charitable Foundation.
Dr. Figueroa’s work has demonstrated the power of epigenetics in uncovering novel biology of myeloid malignancies. Her lab has harnessed this for the discovery of previously unrecognized subtypes and the development of epigenetic biomarkers predictive of response to epigenetic therapies. Finally, her lab has also demonstrated that normal aging is accompanied by epigenetic reprogramming of healthy hematopoietic stem and progenitors cells that may predispose them to age-related malignancies.
OBJECTIVES
At the end of the presentation, participants will be able to:
FACULTY DISCLOSURE:
Dr. Figueroa has indicated that she has no relevant financial relationships with commercial interests.
PLANNING COMMITTEE DISCLOSURE:
Dr. Lazaros Lekakis, Associate Professor, Cellular Therapy, has indicated that he has no relevant financial relationships with commercial interests.
TARGET AUDIENCE:
Faculty, Primary Care Physicians, APRNs, PharmD
ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This article was printed from The Miller School of Medicine Medical News
at the following URL: https://events.med.miami.edu/event/hematology-medical-oncology-grand-rounds/
Copyright © 2024 University of Miami Health System